Aggresome formation and liquid–liquid phase separation independently induce cytoplasmic aggregation of TAR DNA-binding protein 43

Seiji Watanabe¹,², Hidekazu Inami³, Kotaro Oiwa¹,³, Yuri Murata¹, Shohei Sakai¹,², Okiru Komine¹,², Akira Sobue¹,², Yohei Iguchi³, Masahisa Katsuno³ and Koji Yamanaka¹,²

Abstract

Cytoplasmic inclusion of TAR DNA-binding protein 43 (TDP-43) is a pathological hallmark of amyotrophic lateral sclerosis (ALS) and a subtype of frontotemporal lobar degeneration (FTLD). Recent studies have suggested that the formation of cytoplasmic TDP-43 aggregates is dependent on a liquid–liquid phase separation (LLPS) mechanism. However, it is unclear whether TDP-43 pathology is induced through a single intracellular mechanism such as LLPS. To identify intracellular mechanisms responsible for TDP-43 aggregation, we established a TDP-43 aggregation screening system using a cultured neuronal cell line stably expressing EGFP-fused TDP-43 and a mammalian expression library of the inherited ALS/FTLD causative genes, and performed a screening. We found that microtubule-related proteins (MRPs) and RNA-binding proteins (RBPs) co-aggregated with TDP-43. MRPs and RBPs sequestered TDP-43 into the cytoplasmic aggregates through distinct mechanisms, such as microtubules and LLPS, respectively. The MRPs-induced TDP-43 aggregates were co-localized with aggresomal markers and dependent on histone deacetylase 6 (HDAC6), suggesting that aggresome formation induced the co-aggregation. However, the MRPs-induced aggregates were not affected by 1,6-hexanediol, an LLPS inhibitor. On the other hand, the RBPs-induced TDP-43 aggregates were sensitive to 1,6-hexanediol, but not dependent on microtubules or HDAC6. In sporadic ALS patients, approximately half of skein-like TDP-43 inclusions were co-localized with HDAC6, but round and granular type inclusion were not. Moreover, HDAC6-positive and HDAC6-negative inclusions were found in the same ALS patient, suggesting that the two distinct pathways are both involved in TDP-43 pathology. Our findings suggest that at least two distinct pathways (i.e., aggresome formation and LLPS) are involved in inducing the TDP-43 pathologies.

Introduction

Abnormal accumulation of TAR DNA-binding protein-43 (TDP-43) is a pathological hallmark of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by a selective loss of motor neurons, and a subtype of frontotemporal lobar degeneration (FTLD-TDP). TDP-43 is a DNA/RNA-binding protein that is predominantly localized in nuclei and plays multifunctional roles in RNA metabolism, including pre-mRNA splicing, translational control, and mRNA stability. However, in most of the ALS and FTLD-TDP cases, TDP-43 is mislocalized into the cytoplasm and forms inclusion bodies. In addition to this, more than 50 mutations in the TARDBP gene, encoding TDP-43, have been identified as a cause of inherited ALS. These observations suggest that dysfunction of TDP-43 is a significant component of ALS pathogenesis. Thus, understanding the mechanism of TDP-43 aggregation will uncover the mechanistic basis for TDP-43 pathology and neurodegeneration in ALS/FTLD.
Recently, a number of studies revealed that many kinds of RNA-binding proteins (RBPs), including TDP-43, spontaneously develop granule-like structures via a liquid–liquid phase separation (LLPS) mechanism. LLPS is a process in which proteins and nucleotides abruptly segregate into two distinct phases, enabling the formation of intracellular membrane-less organelles, such as p-bodies and stress granules. Under physiological conditions, LLPS enables to achieve high local concentrations for molecular interactions and rapid chemical reactions, and allow fast changes of molecules upon signaling for facilitating various intracellular biological processes, e.g., transcriptional regulation and signal transduction. However, once excess amounts of proteins are accumulated together with dysregulation of LLPS, the complexes quickly transform into pathological inclusions that are often found in neurodegenerative diseases. ALS causative gene products, including FUS, TIA-1, and, of course, TDP-43, are proposed to form aggregates via LLPS. Consistent with this hypothesis, recent studies have discovered that optical multimerization of cytoplasmic TDP-43 induces the aggregation and sequestration of endogenous nuclear TDP-43 into the cytoplasmic aggregates that are dependent on LLPS.

However, whether LLPS is solely responsible for the cytoplasmic aggregation of TDP-43 remains unclear. Among the over 25 inherited ALS/FTLD causative genes, there is a considerable number of the genes encoding the proteins that have the functions different from RNA regulation. For instance, SQSTM1 and TBK1 encode proteins involved in autophagy, while PFN1 and TUBA4A encode cytoskeletal proteins. Considering that TDP-43 pathology is also observed in the most of inherited ALS/FTLD patients, there may be the intracellular mechanisms other than LLPS stimulating the formation of TDP-43 aggregates in ALS/FTLD lesions.

In this study, we aimed to determine the intracellular pathways involved in the formation of TDP-43 aggregates. Using a screening system of cytoplasmic TDP-43 aggregates induced by the expression of inherited ALS/FTLD causative genes, we established that, in addition to the RBPs, microtubule-related proteins (MRPs) also co-aggregated with TDP-43 in the cytoplasm. The MRPs induced co-aggregation of TDP-43 via the formation of aggregatesomes, cytoplasmic aggregations that are dependent on microtubules. In contrast, the RBPs-induced aggregations were dependent on LLPS. Therefore, both the TDP-43 co-aggregation pathways were independent from each other. Moreover, we also showed that a subset of TDP-43 inclusions in spinal motor neurons of sporadic ALS cases were co-localized with histone deacetylase 6 (HDAC6), an aggresome marker. Our findings suggest that at least two distinct pathways (i.e., aggresome formation and LLPS) are involved in inducing the TDP-43 pathologies.

Materials and methods

Antibodies

Antibodies used in this study are as follows; anti-HDAC6 (1:1000 for immunoblotting, 1:50 for immunohistochemistry, #7558, RRID: AB_10891804, Cell Signaling Technology, Danvers, MA, USA), anti-γ-tubulin (1:1000, #ab27074, RRID: AB_2211240, Abcam, Cambridge, UK), anti-vein-inent (1:50, #3932, RRID: AB_2288553, Cell Signaling), anti-TDP-43 (1:1000, clone 3H8, #MABN45, EMD Millipore, Billerica, MA), anti-β-actin (1:5000, #5441, RRID: AB_476744, Sigma-Aldrich Co LLC, St. Louis, MO, USA), anti-RFP (1:1000, #PM005, RRID: AB_591279, Medical & Biological Laboratories (MBL) Co LTD, Nagoya, Japan).

Cell culture and small-interfering RNA (siRNA) transfection

Mouse neuroblastoma Neuro2a (RRID: CVCL_0470) (N2a) cells were maintained and differentiated, as described elsewhere. To establish the cell line stably expressing EGFP-fused human TDP-43 wild-type or nuclear localization signal (NLS)-deficient mutant, we transfected linearized pcDNA3.1(+) (Thermo Fisher Scientific Inc, Waltham, MA, USA) inserted each TDP-43 complementary DNA (cDNA) with Lipofectamine 2000 (Thermo Fisher). The cells were cultured for two weeks in a growth medium containing 1.0 g/L G-418 (Nacalai Tesque, Kyto, Japan). The colonies were isolated and confirmed the expression of EGFP-TDP-43 by fluorescent microscopy and immunoblotting. The established cell lines were maintained in a growth medium containing 1.0 g/L G-418. HeLa (CCL-2) and HEK293 (CRL-1573) cells, both obtained from ATCC, were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 g/L glucose supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (all from Thermo Fisher) at 37°C in a humidified chamber containing 5% CO2. Total RNAs of HeLa and HEK293 cells were isolated using the RNeasy-micro kit (QIAGEN, Hilden, Germany).

Stealth siRNA against the murine Hdac6 gene was obtained from Thermo Fisher. siRNA (20 nM) was transfected into N2a cells using Lipofectamine RNAi Max (Thermo Fisher) as described by the manufacturer.

TDP-43 aggregation screening using mammalian inherited ALS/FTLD causative gene expression library

Full-length wild-type cDNA of each familial ALS causative gene was amplified using the gene-specific primers from cDNA synthesized from total RNA of HeLa or HEK293 cells. The amplified cDNA was inserted into pmCherry-N1/C1 vectors (Clontech Laboratories Inc, Mountain View, CA, USA) using SLiCE reaction. ALS/FTLD-causing mutations were introduced according to
N2a cells stably expressing EGFP-fused TDP-43, which is described above, were seeded at $5.0 \times 10^4$ /well on a 4 well cover-slide chamber (AGC Techno Glass Inc, Shizuoka, Japan) coated with poly-D-lysine. On the next day, 0.25 µg/well plasmids to express inherited ALS/FTLD causative genes were transfected with Lipofectamine 2000 (Thermo Fisher) according to the manufacturer’s guide. After 6 h of the transfection, the medium was changed into a differentiation medium (DMEM + 2%(v/v) fetal bovine serum and 2 mM N6,2′-O-dibutrylcytidine-3′,5′-cyclic monophosphate (Nacalai Tesque, Kyoto, Japan)), and cultured for 48 h. Then, the non-fixed cells were observed using laser scanning confocal microscopy (LSM-700; Carl Zeiss AG, Oberkochen, Germany) and the equipped software (Zen; Carl Zeiss AG).

For the treatment with 1,6-hexanediol (1,6-HD) (Sigma), the medium was replaced with a fresh one with/without 4%(v/v) 1,6-HD and incubated for 10 min at room temperature. Then, the non-fixed cells were observed using laser scanning confocal microscopy.

Immunoblotting and Immunofluorescence

Immunoblotting analyses were performed as described elsewhere. For TDP-43 insolubility assay, the cells were first lysed in TBS supplemented with 1 mM EDTA, 1%(v/v) Triton X-100 and protease inhibitor cocktail by brief sonication on ice. After centrifugation at 15,000 × g, at 4 °C for 5 min, the supernatants were collected as soluble fraction. The pellets were resuspended in TBS supplemented with 1 mM EDTA and 2%(w/v) sodium-dodecyl sulfate (SDS) by brief sonication, then they were subjected to centrifugation at 15,000 × g, room temperature for 5 min. The supernatants were collected as insoluble fractions. Aliquots containing 15 µg/lane of soluble fractions and the same volume of corresponding insoluble fractions were analyzed by immunoblotting. For immunofluorescence analyses of γ-tubulin and vimentin, cultured N2a cells were transfected and cultured in a differentiation medium for 48 h. Then, the cells were fixed with ice-cold methanol at −30 °C for 20 min. After three times wash with TBS (50 mM Tris-HCl (pH 7.4), 150 mM NaCl), the cells were immunostained as described previously. Briefly, the cells were incubated with primary antibodies at 4 °C for overnight, following incubation with secondary antibodies at room temperature for 2 h. Immunofluorescence images were obtained by a confocal laser scanning microscopy (LSM-700; Carl Zeiss AG, Oberkochen, Germany) and the equipped software (Zen; Carl Zeiss AG).

Postmortem human tissues

Specimens of spinal cords from six patients with sporadic ALS and two control patients with other neurological diseases were obtained by autopsy with informed consent (Supplementary Table S1). The diagnosis of ALS was confirmed by El Escorial diagnostic criteria as defined by the World Federation of Neurology. The ethics committee approved the collection of tissues and their use in this study of Nagoya University. We confirmed that informed consent of all the tested subjects were obtained. For immunofluorescence analyses, the sections were prepared from formalin-fixed and paraffin-embedded tissues, deparaffinized, and incubated at 90 °C for 40 min in HistVT One (Nacalai Tesque).

Statistical analyses

All the data from immunofluorescence and semi-quantitative immunoblotting were analyzed by an unpaired t-test for the comparison between two groups, or one-way ANOVA followed by the posthoc Tukey’s multiple comparison t-test for the comparison among more than three groups, respectively. When the values were compared only with the control values, Dunnet’s multiple comparison tests were used instead of Tukey’s one. For all the ANOVA, we used Brown–Forsythe and Welch’s correction not to assume normal distribution of the data. All the statistical analyzes were carried out using GraphPad Prism software (GraphPad Software, La Jolla, CA).

Results

TDP-43 co-aggregation screening reveals the involvement of microtubule-related proteins (MRPs) and RNA-binding proteins (RBPs) in cytoplasmic TDP-43 aggregation

To identify intracellular pathways involved in cytoplasmic TDP-43 aggregation, we established a screening system for the co-aggregation of TDP-43 and ALS/FTLD causative proteins (Fig. 1A). We generated N2a cells that stably expressed EGFP-fused wild-type or NLS-defective TDP-43 (TDP-43WT or TDP-43ΔNLS, respectively) as reporter cell lines to visualize TDP-43 aggregates (Fig. 1B). When both the cells were cultured in normal conditions, no TDP-43 aggregates were observed. We also prepared an inherited ALS/FTLD causative gene expression library (19 genes in total, see Table 1). The library consisted of expression plasmids of mCherry-fused wild-type or two independent variants carrying ALS/FTLD-linked mutations for each of the genes. Then, we transfected each plasmid into the reporter cells and observed them after two days of incubation. We then screened the library to identify the ALS/FTLD genes that induce cytoplasmic TDP-43 aggregation in N2a reporter cells that stably express EGFP-TDP-43ΔNLS. The screening results are summarized in Table 1. Our screening identified that 14/19 (74%) gene products formed intracellular aggregates and 9 of them (9/19 in total, 47%) co-aggregated with TDP-43ΔNLS. Representative images for the cells expressing each of the inherited ALS/FTLD
Fig. 1 (See legend on next page.)
causative genes are shown in Supplementary Fig. S1. We also found that the ALS/FTLD causative gene products are classified into three groups: gene products that induce co-aggregates with TDP-43 (Group 1) (Fig. 1C, F, G), gene products that induce aggregates without TDP-43 (Group 2) (Fig. 1D, F, G), and gene products that do not form aggregates (Group 3) (Fig. 1E–G).

More importantly, all of the gene products in Group 1 induced cytoplasmic translocation and aggregation of TDP-43ΔNLS (Fig. 2A and Supplementary Fig. S2). Interestingly, the Group 1 genes were involved in either microtubular dynamics or RNA regulation, suggesting that these two pathways are both involved in intracellular TDP-43 aggregation. Therefore, to determine the mechanisms of intracellular TDP-43 aggregation, we further classified Group 1 genes into microtubule-related proteins (MRPs;PFN1, UBQLN2, TUBA4A, and CHMP2B) and RNA-binding proteins (RBPs; FUS, TAF15, TIA1, and MART3) (Fig. 2B). Notably, the genes encoding RBPs-induced TDP-43 co-aggregation only when their mutants were mislocalized into the cytoplasm, suggesting that leakage of RBPs from nuclei is closely associated with the cytoplasmic TDP-43 aggregation.

Furthermore, we also confirmed that the fluorescent-based screening results (Figs. 1 and 2) are well consistent with the results of TDP-43 insolubility assay (Fig. 3). The ALS/FTLD causative genes classified into Group 1 specifically decreased solubility of both TDP-43ΔNLS, EGFP (Fig. 3B) and endogenous TDP-43 (Fig. 3C), supporting with the results of TDP-43 insolubility assay (Fig. 3). The image expressing a control plasmid is shown in Fig. 2B. A total of 19 ALS/FTLD causative genes were classified into three groups: Group 1, genes that induce co-aggregates with TDP-43ΔNLS (Fig. 3G); Group 2, genes that induce aggregates without TDP-43ΔNLS (D); and Group 3, genes that do not form aggregates in the cells (E). The entire screening results are shown in Supplementary Fig. S1. Arrowheads in C indicate co-aggregates of the transfected proteins with TDP-43. Arrows in D indicate aggregates of the transfected proteins excluding TDP-43. Scale bars = 20 μm. F, G Quantification of N2a cells with aggregates of ALS/FTLD causative gene products (F) and the ratio of co-aggregation with TDP-43 (G). Data are expressed as mean ± standard error of the means (SEM) (n = 3). More than 50 cells were counted for the quantification.

**Liquid–liquid phase separation (LLPS) is involved in RBPs-induced TDP-43 aggregation**

Co-transfection of MRP (PFN1ΔC71G) and RBP (FUSP525L) in N2a reporter cells stably expressing EGFP-TDP-43ΔNLS revealed that the aggregates induced by MRPs and RBPs were distinctly partitioned in cytoplasm (Supplementary Fig. S3). These results suggest that the mechanisms of MRPs- and RBPs-induced TDP-43 aggregation are independent of each other. Previous studies reported that FUS and TIA-1, representative RBPs classified into Group 1, form cytoplasmic aggregates through LLPS24–25. Thus, to investigate the mechanism of RBPs-induced aggregation, we treated the cells with 1,6-hexanediol (1,6-Hd), an inhibitor of LLPS, to assess the involvement of LLPS in the co-aggregation of RBPs and TDP-43. As shown in Fig. 4A, B, 1,6-Hd drastically dissociated the cytoplasmic aggregates of RBPs, mutant FUS and TIA1. Consistent with the decreased number of RBPs-induced aggregates, sequestration of TDP-43 into the aggregates was also significantly prevented (Fig. 4C). These observations suggest that LLPS drives the cytoplasmic co-aggregation of RBPs and TDP-43. In contrast, 1,6-Hd did not influence either the number of aggregates of MRPs (mutant PFN1 and UBQLN2) or co-aggregates with TDP-43 (Fig. 4A–C), suggesting that a mechanism independent of LLPS drives the co-aggregation of MRPs and TDP-43.

**MRPs-induced TDP-43 co-aggregates are sensitive to nocodazole and co-localized with aggresomal markers**

To examine whether the microtubules are essential for MRPs-induced TDP-43 aggregation, we then treated the cells with nocodazole, a microtubule destabilizing reagent. As expected, the nocodazole treatment substantially reduced the amount of co-aggregates of MRPs (PFN1C71G) and TDP-43 (Fig. 5A, B). Intriguingly, the co-aggregates of MRPs and TDP-43 were co-localized with the aggresomal markers γ-tubulin (Fig. 5C) and vimentin (Fig. 5D). An aggresome is a peri-nuclear compartment where misfolded proteins accumulate26–27. Once the cellular protein degradation system is overwhelmed, the misfolded proteins are accumulated into aggresomes through microtubules for a cellular defense. Therefore, our findings suggest that TDP-43 is sequestered into aggregates of MRPs during aggresome formation. Meanwhile, RBPs-induced TDP-43 co-aggregates (FUSP525L) were not affected by nocodazole (Fig. 5A) and did not co-localize with aggresomal markers (Fig. 5C, D), suggesting that MRPs and RBPs sequester TDP-43 into their aggregates through distinct mechanisms.

**Histone deacetylase 6 is associated with the co-aggregation of MRPs and TDP-43**

Histone deacetylase 6 (HDAC6) recognizes misfolded proteins and transports them to aggresomes through microtubules28. Previous reports showed that aggresomes...
| Functions                  | Gene symbol | Mutations | Localization     | Aggregation | Co-aggregation with TDP-43 | TDP-43 inclusions in inherited ALS cases | Co-localization with TDP-43 inclusions | References |
|----------------------------|-------------|-----------|------------------|-------------|--------------------------|--------------------------------------|---------------------------------|------------|
| RNA-binding proteins       | TARDBP      | Wild-type | Nuclear           | –           | –                        | Yes43-45                             | –                               | 1. Pamphlett et al.43 |
| (ALS10)                    | M337V       | Nuclear   | –                | –           | –                        | –                                    | –                               | 2. Van Deurzen et al.44 |
|                            | G348C       | Nuclear   | –                | –           | –                        | –                                    | –                               | 3. Yokoseki et al.45 |
|                            | ΔNLS        | Nuclear   | –                | –           | –                        | –                                    | –                               | 4. Yokoseki et al.45 |
| FUS                       | Wild-type   | Nuclear   | –                | –           | –                        | No46,47                              | –                               | 1. Kiviatkowski et al.46 |
| (ALS6)                     | R521C       | Nuclear   | –                | –           | –                        | (Yes in sporadic ALS32)              | –                               | 2. Vance et al.50 |
|                            | P525L       | Cytosol   | ++               | ++          | –                        | –                                    | –                               | 3. Ikenaka et al.52 |
| HNRNPA1                   | Wild-type   | Nuclear   | –                | –           | –                        | –                                    | –                               | 1. Kim et al.58 |
| (ALS20)                    | D314V       | Nuclear   | –                | –           | –                        | –                                    | –                               | 2. Tada et al.59 |
|                            | N319S       | Nuclear   | –                | –           | –                        | –                                    | –                               | 3. Tada et al.59 |
| MATR3                     | Wild-type   | Nuclear   | –                | –           | –                        | Yes60,61                             | Yes60,61                         | 1. Johnson et al.60 |
| (ALS21)                    | S85C        | Nuclear   | –                | –           | –                        | –                                    | –                               | 2. Tada et al.61 |
|                            | F115C       | Nuclear + cytosol | +   | +            | –                        | –                                    | –                               | 3. Tada et al.61 |
| TAFT5                     | Wild-type   | Nuclear + cytosol | +   | ++           | –                        | –                                    | –                               | 1. Hirsch-Reinshagen et al.54 |
|                            | G391E       | Nuclear + cytosol | +   | ++           | –                        | –                                    | –                               | 2. Mackenzie et al.55 |
|                            | R408C       | Nuclear + cytosol | +   | +            | –                        | –                                    | –                               | 3. Fahed et al.56 |
| TIA1                      | Wild-type   | Nuclear + cytosol | +   | ++           | –                        | Yes58,59                             | Yes58/No59                      | 1. Hirsch-Reinshagen et al.54 |
|                            | P362L       | Nuclear + cytosol | +   | +            | –                        | –                                    | –                               | 2. Mackenzie et al.55 |
|                            | A381T       | Nuclear + cytosol | +   | +            | –                        | –                                    | –                               | 3. Fahed et al.56 |
| Intracellular trafficking  | FG4         | Wild-type | Cytosol          | +           | –                        | –                                    | –                               | 1. Caims et al.51 |
| (ALS11)                    | Q403X       | Cytosol   | +                | –           | –                        | –                                    | –                               | 2. Neumann et al.52 |
|                            | V654A       | Cytosol   | +                | –           | –                        | –                                    | –                               | 3. Gitch et al.53 |
| CHMP2B                    | Wild-type   | Cytosol   | +                | +            | No                       | –                                    | –                               | 1. Caims et al.51 |
| (ALS17)                    | L29V        | Cytosol   | +                | +            | No                       | –                                    | –                               | 2. Neumann et al.52 |
|                            | Q206H       | Nuclear + cytosol | +   | +            | –                        | –                                    | –                               | 3. Gitch et al.53 |
| TFG                       | Wild-type   | Cytosol   | +++              | –            | –                        | –                                    | –                               | 1. Caims et al.51 |
|                            | G269V       | Cytosol   | +++              | –            | –                        | –                                    | –                               | 2. Neumann et al.52 |
|                            | P285L       | Cytosol   | +++              | –            | –                        | –                                    | –                               | 3. Gitch et al.53 |
| Protein degradation        | ICP         | Wild-type | Cytosol          | –           | –                        | Yes55-56                             | Not reporter (Yes in cultured cells57) | 1. Caims et al.51 |
| (ALS14)                    | R159H       | Cytosol   | –                | –            | –                        | –                                    | –                               | 2. Neumann et al.52 |
|                            | A232E       | Cytosol   | –                | –            | –                        | –                                    | –                               | 3. Gitch et al.53 |
| UBQLN2                    | Wild-type   | Cytosol   | +++              | +++          | Yes54-55                 | Yes56 (Yes in cultured cells57)      | –                               | 1. Deng et al.54 |
| (ALS15)                    | P497H       | Cytosol   | +++              | +++          | Yes56 (Yes in cultured cells57) | –                                    | –                               | 2. Williams et al.55 |
|                            | P506T       | Cytosol   | +++              | +++          | Yes56 (Yes in cultured cells57) | –                                    | –                               | 3. Fahed et al.56 |
| SQSTM1                    | Wild-type   | Cytosol   | ++               | –            | Yes                       | –                                    | –                               | 1. Kovacs et al.57 |
| (FTLD-ALS3)                | P392L       | Cytosol   | ++               | –            | Yes                       | –                                    | –                               | 2. Gijselinck et al.59 |
|                            | G425R       | Cytosol   | ++               | –            | Yes                       | –                                    | –                               | 3. Gijselinck et al.59 |
| TBK1                      | Wild-type   | Cytosol   | –                | –            | Yes58,59                  | Not reported                         | –                               | 1. Freischmidt et al.58 |
| (FTLS-AL54)                | K401E       | Cytosol   | –                | –            | –                        | –                                    | –                               | 2. Gijselinck et al.59 |
| Functions                        | Gene symbol | Mutations | Localization | Aggregation | Co-aggregation with TDP-43 | TDP-43 inclusions in inherited ALS cases | Co-localization with TDP-43 inclusions | References |
|---------------------------------|-------------|-----------|--------------|-------------|-----------------------------|-------------------------------------------|-----------------------------------------|------------|
| Cytoskeleton                    | TDP-43      | Δ690-713  | Cytosol      | –           | –                           | Not reported                              | –                                       |            |
|                                 |             | Wild-type | Nuclear      | –           | –                           | Not reported                              | –                                       |            |
|                                 |             | S509P     | Nuclear      | –           | –                           | Not reported                              | –                                       |            |
|                                 |             | S621G     | Nuclear      | –           | –                           | Not reported                              | –                                       |            |
| Cytoskeleton                    | PFN1        | Wild-type | Cytosol      | –           | –                           | Yes60,61                                  | Not reported (Yes in cultured cells61) | 1. Wu et al.60 |
| (ALS18)                         |             | C71G      | Cytosol      |++          |+++                         | Not reported                              | –                                       |            |
|                                 |             | M114T     | cytosol      |–           |–                           | Not reported                              | –                                       |            |
|                                 | TUBA4A      | Wild-type | Cytosol      |++          |++                          | Not reported                              | –                                       |            |
| (ALS22)                         |             | R320H     | Cytosol      |++          |++                          | Not reported                              | –                                       |            |
|                                 |             | W407X     | Cytosol      |++          |++                          | Not reported                              | –                                       |            |
| ER stress response              | VAPB        | Wild-type | er           | –           | –                           | Not reported                              | –                                       |            |
| (ALS8)                          |             | T48I      | er           | –           | –                           | Not reported                              | –                                       |            |
|                                 |             | P56S      | er           |++          |–                           | Not reported                              | –                                       |            |
| Growth hormone receptor         | ERBB4       | Wild-type | er + cell surface | –       | –                           | Not reported                              | –                                       |            |
| (ALS19)                         |             | R927Q     | er + cell surface | –       | –                           | Not reported                              | –                                       |            |
| Mitochondrial homeostasis       | CHCHD10     | Wild-type | Mito         | –           | –                           | Not reported                              | –                                       |            |
| (FTLD-ALS2)                     |             | P34S      | Mito         | –           | –                           | Not reported                              | –                                       |            |
|                                 |             | S59L      | Mito         | –           | –                           | Not reported                              | –                                       |            |

"Aggregation" was evaluated by ratio with intracellular aggregates of each gene product. +: mild (<30%), ++: medium (30-70%), +++: severe (>70%). Co-aggregation with TDP-43 was evaluated co-localization of TDP-43 aggregates and aggregates of each gene product. +: partially, ++: completely. More than 50 cells were counted in each trial (n = 3 each).
are involved in the formation of inclusion bodies in the lesions of neurodegenerative diseases such as Huntington’s disease. Therefore, we next examined whether the elimination of Hda6 by siRNA affected TDP-43 co-aggregation with MRPs in N2a cells (Fig. 6A). As shown in Fig. 6B–D, Hda6 knock-down prevented the aggregation of MRPs, as well as TDP-43 co-aggregation with MRPs. Interestingly, relatively small cytoplasmic aggregates of MRPs were still observed in the cells with Hda6 knock-down (Fig. 6B, asterisks); however, TDP-43 was not co-localized with them. Since HDAC6 is crucial for the transport of misfolded proteins to aggresomes, this observation might suggest that TDP-43 is sequestered during compartmentalization. On the other hand, the Hda6 knock-down did not affect RBPs-induced TDP-43 co-aggregation, indicating that Hda6 was not involved in the TDP-43 sequestration into the LLPS-induced aggregates.

Different characteristics of TDP-43 inclusions in sporadic ALS suggest multiple pathways form TDP-43 pathology

The results of TDP-43 co-aggregation obtained by our screening system are based on the overexpression of the inherited ALS/FTLD causative genes. However, it is unclear whether the mechanisms for the formation of TDP-43 aggregation observed in our study are involved in the TDP-43 pathology of sporadic ALS. To examine the involvement of the aggresome pathway in TDP-43 pathology, we examined the co-localization of TDP-43 and HDAC6, an aggresomal marker, in spinal motor neurons of sporadic ALS patients. We found that approximately half of TDP-43 skein-like inclusions were co-localized with HDAC6 (75/160, 46.9% of total skein-like inclusions) (Fig. 7A, B). It should be noted that no co-localization of TDP-43 and HDAC6 was observed in round (0/52) or granular (0/33) TDP-43 inclusions. These observations support the hypothesis that TDP-43
skein-like inclusions are, at least partially, formed by a similar mechanism to aggresome formation. Importantly, both the HDAC6-positive and HDAC6-negative inclusions were found in every sporadic ALS patient, suggesting that the mechanisms of TDP-43 aggregation vary in each of the neurons. In conclusion, the different characteristics between skein-like and other types of TDP-43 inclusions suggest that TDP-43 pathology is developed via multiple complexed mechanisms, likely including both aggresome formation and LLPS, in sporadic ALS.

**Discussion**

In this study, we demonstrated that: (i) at least two distinct intracellular pathways were involved in TDP-43 cytoplasmic aggregation, including aggresome formation and LLPS; (ii) the two pathways were independent of each other; and (iii) in spinal motor neurons of sporadic ALS, both HDAC6-positive and HDAC6-negative aggregates were found in the same ALS patient. Therefore, to the best of our knowledge, we are the first to confirm that HDAC6-dependent aggresome formation is partially involved in skein-like TDP-43 inclusion of sporadic ALS.

Our study revealed that over 70% of the examined inherited ALS/FTLD causative 19 genes induced TDP-43 co-aggregation in cultured neuronal cells and the fluorescent-based observation of TDP-43 co-aggregates was well consistent with the TDP-43 insolubility examined by immunoblotting. Our screening system enabled us to assess whether any genes of interest induce cytoplasmic TDP-43 aggregation by a simple transfection-based screening. Moreover, our screening system has been proved useful for investigating the mechanism of TDP-43 aggregation. Indeed, as described above, we identified two distinct mechanisms involved in TDP-43 aggregation by using this system (i.e., aggresome formation and LLPS). Our screening system will also be useful for identifying compounds that prevent cytoplasmic TDP-43 aggregation, which may contribute to a novel therapeutic strategy for ALS/FTLD.

Although our screening system generally well recapitulated cytoplasmic TDP-43 aggregation in ALS/FTLD, our results were partially inconsistent with some previous reports on the pathology of inherited ALS. Notably, we did not find any evidence of TDP-43 aggregation in the neuronal cells expressing the inherited ALS/FTLD causative genes related to protein degradation (e.g., VCP, UBQLN2, SQSTM1, and TBK1), although the previous studies reported TDP-43 pathology in inherited ALS patients with these mutations. Moreover, the co-localization of TDP-43 and the inherited ALS/FTLD causative gene products are still controversial even though TDP-43 pathology is widely observed in the patients with ALS. For example, some studies have suggested the co-localization of TDP-43 with TIA-1 or FUS but other studies do not. One possible interpretation of this inconsistency is an experimental limitation of our screening system based on the overexpression of the inherited ALS/FTLD causative genes with a short incubation time before evaluation. Therefore, a careful interpretation is required to compare our results with the inherited ALS/FTLD neuropathology data.

The co-aggregation of TDP-43 and RBPs was sensitive to 1,6-Hd, suggesting that LLPS drives cytoplasmic RBP-induced aggregation. Nucleotides, enriched in nuclei, prevent aggregation driven by LLPS. Indeed, the previous study demonstrated that an artificially designed RNA, which specifically binds to TDP-43, prevents intracellular aggregation of TDP-43 triggered by light-driven forced multimerization of TDP-43 in the cytoplasm. This
Fig. 4 Liquid-liquid phase separation (LLPS) is involved in RBP-induced TDP-43 co-aggregation. Administration of 1,6-hexanediol (1,6-Hd), an inhibitor of LLPS, dissociated TDP-43 co-aggregates with RBPs but not with MRPs in N2a cells expressing TDP-43 ΔNLS-EGFP. Representative images are shown in A. Both the ratio of the cells with TDP-43 aggregates (B) and TDP-43 co-aggregation (C) were reduced, specifically in the cells expressing RBPs with 1,6-Hd. Arrowheads indicate co-aggregates of the RBPs and MAPs with TDP-43 ΔNLS-EGFP. Whereas, asterisks indicate the cells without co-aggregates of the RBPs by the 1,6-Hd treatment. More than 50 cells in each condition were analyzed for the quantification. Data are expressed as mean ± SEM (n = 3).
mechanism could explain our observations that RBPs only aggregated with TDP-43 when they leaked from nuclei into the cytoplasm. On the other hand, the MRPs-induced co-aggregation of TDP-43 was dependent on aggresome formation. The role of aggresomes in the accumulation of misfolded proteins has been pointed out in various neurodegenerative diseases. ALS-linked PFN1 mutant proteins that aggregated in the cytoplasm were dependent on microtubules, which was similar to our observations. Intriguingly, these two pathways of TDP-43 aggregation are not complementary and are independent of each other. Inhibiting LLPS prevented RBPs-mediated TDP-43 aggregation, but did not affect MRPs-induced TDP-43 aggregation. Conversely, HDAC6 suppression and microtubular destabilization only affected MRPs-induced TDP-43 aggregation. All these observations indicate that targeting the intracellular mechanism specific to each pathway is key to preventing TDP-43 accumulation. Nonetheless, there is still a possibility that other independent pathways are also involved in cytoplasmic TDP-43 aggregation. Further investigation into the potential mechanisms of TDP-43 accumulation is required.

HDAC6 is a key molecule in aggresome formation. HDAC6 facilitates the transport of misfolded proteins by connecting microtubules and ubiquitinated proteins. The involvement of HDAC6 has been reported in various neurodegenerative diseases such as Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease. In ALS, it was reported that deletion of Hdac6 ameliorates the disease progression in SOD1-ALS mice and TDP-43 deficiency drastically reduces HDAC6 expression in cultured cells. Moreover, HDAC6 inhibition reversed
Fig. 6 Histone deacetylase 6 (Hdac6) is involved in MRPs-induced TDP-43 co-aggregation. A Confirmation of Hdac6 knock-down in N2a cells by the treatment with siRNA (siHdac6). The expression levels relative to the control siRNA treated samples (siCtrl) were shown. B–D Hdac6 suppression specifically prevented MRPs-induced TDP-43 co-aggregation but not RBPs. Representative images are shown in B. Arrowheads indicate co-aggregates of the MRPs and RBPs with TDP-43ΔNLS-EGFP. Whereas, asterisks indicate the cells without co-aggregates of the MRPs by Hdac6 suppression. The ratio of the cells with MRPs aggregates (C) and the ratio of MRPs and TDP-43 co-aggregation were substantially reduced, specifically by siHdac6 treatment (D). More than 50 cells in each condition were analyzed for the quantification. All the data are expressed as mean ± SEM (n = 3).
axonal transports, which are defective in iPSC-derived motor neurons from ALS patients with FUS mutation41. These observations suggest the possibility that HDAC6 is also involved in the ALS pathology similar to other neurodegenerative diseases and that it may be a therapeutic target for ALS through restoring axonal transport. In addition to this, our results strengthen the possibility that inhibition of HDAC6 is a potential therapeutic target for ALS by providing a novel mechanism for preventing microtubule-dependent TDP-43 pathology. HDAC6 inhibition is probably effective for MRP-linked inherited ALS and partially to sporadic ALS.

Since most of the ALS cases are sporadic, it is important to identify the mechanism responsible for TDP-43 aggregation in the sporadic ALS. Recent reports showed that cytoplasmic TDP-43 was sequestered into aggregates of MRPs in N2a cells and approximately half of TDP-43 skein-like inclusions in sporadic ALS patients were co-localized with HDAC6, an aggresomal marker. Our results suggest that the HDAC6-dependent aggresome pathway may be involved in the formation of skein-like inclusion in ALS/FTLD. However, we also found that both HDAC6-positive and HDAC6-negative skein-like inclusions were observed in the same sporadic ALS patient, as shown in Fig. 7B. In addition, the round and granular inclusions, which are not co-localized with HDAC6, were also found in the same sporadic ALS patient. These observations suggest that the mechanisms responsible for TDP-43 aggregation are different from each other among the remaining motor neurons in the one sporadic ALS patient and that the morphology of TDP-43 inclusions may reflect the corresponding intracellular mechanism. Further studies are needed to determine the mechanism responsible for each type of cytoplasmic TDP-43 aggregation in motor neurons. We found that the two distinct pathways, aggresome formation and LLPS, are independently involved in the formation of cytoplasmic TDP-43 inclusions in ALS. Although it is unclear whether each type of cytoplasmic TDP-43 aggregates provokes toxicities to neurons, our findings, together with the other studies, suggest the therapeutic potential of HDAC6 through the several lines of mechanisms in ALS/FTLD.

Acknowledgements
This work was supported by Grants-in-Aid for Scientific Research 18H02740, 18H04860, 19K02114 (to K.Y.), and 17H04986 (to S.W.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan/Japan Society for the Promotion of Science (JSPS), AMED under Grant Number 20ek0109426h0001 (K.Y.), Uehara Memorial Foundation (K.Y. and S.W.), and the Public Foundation of Chubu Science and Technology Center (S.W.).

Author details
1Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi 464-8601, Japan.
2Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
3Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
4Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi 464-8601, Japan.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-020-03116-2).

Received: 2 July 2020 Revised: 6 October 2020 Accepted: 8 October 2020 Published online: 23 October 2020

References
1. Lee, E. B., Lee, V. M. & Trojanowski, J. Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38-50 (2011).
1. Ling, S. C., Polymenidou, M. & Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416–438 (2013).

2. Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A. & Patel, B. K. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol. Neurosci. 12, 25 (2019).

3. Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602–611 (2006).

4. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).

5. Burati, E. Functional significance of TDP-43 mutations in disease. Adv. Genet. 91, 1–53 (2015).

6. Harrison, A. F. & Shorter, J. RNA-binding proteins with prion-like domains in disease. J. Biol. Chem. 294, 14823–14835 (2019).

7. Hyman, A. A., Weber, C. A. & Julicher, F. Liquid-liquid phase separation in biology. Annu. Rev. Dev. Biol. 30, 39–58 (2014).

8. Luo, Y., Na, Z. & Slavoff, S. A. P-bodies: composition, properties, and functions. Biochemistry 57, 2424–2431 (2018).

9. Liang, S. C., Polymenidou, M. & Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Science 344, 265–269 (2014).

10. Liu, Y. S., Hasegawa, M., Fischbeck, K. H., Hasegawa, M. & Ishihara, K. Inclusion body formation and aggregation of TDP-43 in familial amyotrophic lateral sclerosis type 6. J. Neuropathol. Exp. Neurol. 75, 1208–1211 (2006).

11. Tanaka, Y., Hasegawa, M., Fischbeck, K. H. & Ishihara, K. Mutations in TDP-43 cause familial amyotrophic lateral sclerosis type 6. Science 323, 1205–1208 (2009).

12. Kim, H. J. et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multifocal motor neuropathy. Sci. Rep. 7, 474 (2017).

13. Liang, S. C., Polymenidou, M. & Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Science 344, 265–269 (2014).

14. Watanabe et al. Cell Death Disease (2020) 11:909
56. Fahed, A. C. et al. UQQLN2 mutation causing heterogeneous X-linked dominant neurodegeneration. Ann. Neurol. 75, 793–798 (2014).
57. Kovacs, G. G. et al. Clinicopathological description of two cases with gene mutation associated with frontotemporal dementia. Neuropathology 36, 27–38 (2016).
58. Freischmidt, A. et al. Haploinsufficiency of TBK1 causes familial ALS and frontotemporal dementia. Nat. Neurosci. 18, 631–636 (2015).
59. Gijselinck, I. et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 15, 2116–2125 (2015).
60. Wu, C. H. et al. Mutations in the prolin 1 gene cause familial amyotrophic lateral sclerosis. Nature 488, 499–503 (2012).
61. Smith, B. N. et al. Novel mutations support a role for Prolin 1 in the pathogenesis of ALS. Neurobiol. Aging 36, 1602.e17–1602.e27 (2015).